aTyr Pharma Q2 net loss narrows

aTyr Pharma

07/08/2026 21:17

Overview
US biotech firm posted Q2 net loss of $10.3 mln vs loss of $19.5 mln year ago
Company announced 60% workforce reduction to focus on efzofitimod in ILD
Ended Q2 2026 with $58.9 mln cash, expects runway into late 2028

Outlook
Company expects FDA feedback on Phase 3 efzofitimod protocol by end-August 2026
aTyr Pharma expects topline results from Phase 2 SSc-ILD study in Q1 2027
Company projects annualized operating expenses to decrease by $13 mln from Q4 2026

Result Drivers
CLINICAL MILESTONES - Enrollment completed in Phase 2 EFZO-CONNECT study for SSc-ILD

Company press release: ID:nGNX65nbnl

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Operating Expenses
 
$10.90 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for aTyr Pharma Inc is $3.50, about 597.2% above its August 6 closing price of $0.50

Reuters Recommended Reads
Aug 5 - Emergent BioSolutions swings to Q2 loss on impairment charge; to cut jobs
Aug 5 - Immuneering expects cash runway to fund operations into 2029
Aug 5 - United Therapeutics Q2 revenue misses estimates on Ebulized Tyvaso weakness

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)